These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dimeric Glycoprotein VI Binds to Collagen but Not to Fibrin. Ebrahim M; Jamasbi J; Adler K; Megens RTA; M'Bengue Y; Blanchet X; Uhland K; Ungerer M; Brandl R; Weber C; Elia N; Lorenz R; Münch G; Siess W Thromb Haemost; 2018 Feb; 118(2):351-361. PubMed ID: 29378359 [TBL] [Abstract][Full Text] [Related]
4. Differential Inhibition of Human Atherosclerotic Plaque-Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies: Functional and Imaging Studies. Jamasbi J; Megens RT; Bianchini M; Münch G; Ungerer M; Faussner A; Sherman S; Walker A; Goyal P; Jung S; Brandl R; Weber C; Lorenz R; Farndale R; Elia N; Siess W J Am Coll Cardiol; 2015 Jun; 65(22):2404-15. PubMed ID: 26046734 [TBL] [Abstract][Full Text] [Related]
5. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Kuijpers MJ; van der Meijden PE; Feijge MA; Mattheij NJ; May F; Govers-Riemslag J; Meijers JC; Heemskerk JW; Renné T; Cosemans JM Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1674-80. PubMed ID: 24855058 [TBL] [Abstract][Full Text] [Related]
6. Tissue factor and atherothrombosis. Saha D; S S; Sergeeva EG; Ionova ZI; Gorbach AV Curr Pharm Des; 2015; 21(9):1152-7. PubMed ID: 25312727 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin. Ahmed MU; Kaneva V; Loyau S; Nechipurenko D; Receveur N; Le Bris M; Janus-Bell E; Didelot M; Rauch A; Susen S; Chakfé N; Lanza F; Gardiner EE; Andrews RK; Panteleev M; Gachet C; Jandrot-Perrus M; Mangin PH Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2127-2142. PubMed ID: 32698684 [TBL] [Abstract][Full Text] [Related]
8. Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model. Kuijpers MJ; Gilio K; Reitsma S; Nergiz-Unal R; Prinzen L; Heeneman S; Lutgens E; van Zandvoort MA; Nieswandt B; Egbrink MG; Heemskerk JW J Thromb Haemost; 2009 Jan; 7(1):152-61. PubMed ID: 18983512 [TBL] [Abstract][Full Text] [Related]
9. Anti-GPVI nanobody blocks collagen- and atherosclerotic plaque-induced GPVI clustering, signaling, and thrombus formation. Jooss NJ; Smith CW; Slater A; Montague SJ; Di Y; O'Shea C; Thomas MR; Henskens YMC; Heemskerk JWM; Watson SP; Poulter NS J Thromb Haemost; 2022 Nov; 20(11):2617-2631. PubMed ID: 35894121 [TBL] [Abstract][Full Text] [Related]
10. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions. Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543 [TBL] [Abstract][Full Text] [Related]
11. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation. Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920 [TBL] [Abstract][Full Text] [Related]
12. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Badimon JJ; Lettino M; Toschi V; Fuster V; Berrozpe M; Chesebro JH; Badimon L Circulation; 1999 Apr; 99(14):1780-7. PubMed ID: 10199872 [TBL] [Abstract][Full Text] [Related]
13. Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin. Colace TV; Muthard RW; Diamond SL Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1466-76. PubMed ID: 22516070 [TBL] [Abstract][Full Text] [Related]
14. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511 [TBL] [Abstract][Full Text] [Related]
15. EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis. Grothusen C; Umbreen S; Konrad I; Stellos K; Schulz C; Schmidt B; Kremmer E; Teebken O; Massberg S; Luchtefeld M; Schieffer B; Gawaz M Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1184-90. PubMed ID: 17347483 [TBL] [Abstract][Full Text] [Related]
18. Glycoprotein VI - novel target in antiplatelet medication. Borst O; Gawaz M Pharmacol Ther; 2021 Jan; 217():107630. PubMed ID: 32681846 [TBL] [Abstract][Full Text] [Related]
19. The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity. Smith CW; Harbi MH; Garcia-Quintanilla L; Rookes K; Brown H; Poulter NS; Watson SP; Nicolson PLR; Thomas MR J Thromb Haemost; 2022 Dec; 20(12):2939-2952. PubMed ID: 36239466 [TBL] [Abstract][Full Text] [Related]
20. Anti-GPVI Fab reveals distinct roles for GPVI signaling in the first platelet layer and subsequent layers during microfluidic clotting on collagen with or without tissue factor. Zhang Y; Trigani KT; Shankar KN; Crossen J; Liu Y; Sinno T; Diamond SL Thromb Res; 2022 Oct; 218():112-129. PubMed ID: 36037547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]